Amgen Inc. DL-Notes 2023(23/28)
- BID
100.625
- ASK
100.694
- 500,000 Nom.500,000 Nom.
- 07/27, 20:43:28 PM
Type of financial instrument
Corporate Bond
Sub-Type
Health Care
Yield
4.80
Yield spread Bundesanleihe
2.0236
Tradable for private investors
No
Minimum amount tradeable unit
2,000.00
Maturity
02/03/2028
Interest Rate
5.15 %
Currency
US Dollar
Facts & figures
Price data
| TRADE PLATFORM | ||
| LAST PRICE / YIELD | 100.618 G / 4.80 | 0 Units |
| PRICE DETERMINATION TIME | 07/27/2026 / 08:01:33 PM | |
| DAILY VOLUME (NOMINAL) | 0 | |
| YIELD SPREAD | 2.0236 | |
| FIXINGPRICE | - | |
| DAILY HIGH / LOW | 100.65 | 100.61 |
| PREV. DAY'S PRICE | 100.564 | (07/24) |
| CHANGE DAY BEFORE | +0.05 | 0.05 % |
| 52 WEEK HIGH / LOW | 102.714 (09/08) | 100.54 (07/24) |
Master Data
| WKN | A3LEH4 |
| ISIN | US031162DP23 |
| SYMBOL | - |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Corporate Bond |
| SUB-TYPE | Health Care |
| ISSUER | Amgen Inc. |
| S&P RATING | Please log in to view this field |
| (TRADING) SEGMENT / TICKS | -/ - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| INTEREST RATE | 5.15 % |
| INTEREST RUN FROM | 02/03/2023 |
| NEXT INTEREST PAYMENT | 02/09/2026 |
| UNIT INTEREST FROM NOMINAL AMMOUNT | 2.103 % |
| TRADING CURRENCY / NOTATION | US Dollar/ Percent |
| NOMINAL CURRENCY | US Dollar |
| SETTLEMENT CURRENCY | Euro |
| QUOTATION | Continuous trading |
| ISSUING VOLUME | 3.75 Bil. |
| MINIMUM AMOUNT TRADEABLE UNIT | 2,000.00 |
| SMALLEST TRADEABLE UNIT | 1,000.00 |
| MATURITY | 02/03/2028 |
| MARKET MAKER | - |
| STEP UP/ DOWN WHEN RATING CHANGES | No |
| STEP UP FIXED AT ISSUE | No |
| STEP DOWN FIXED AT ISSUE | No |
| BOND CALLABLE BY THE ISSUER | Yes |
| BOND IS SUBORDINATED | No |
Description
Anleihe kündbar. Make Whole Call Option. Fremdwährungsanleihe: US-Dollar (USD).
Tradability Information
Please log in to see the tradability information for this stock.Not registered yet? Create your free account here.
Company profile
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.